Article Sidebar
Views pdf: 234
PREVALENCE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME
Main Article Content
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among patients with metabolic cardiovascular risk factors. This study was conducted to determine the prevalence of MASLD in patients with metabolic syndrome (MetS). Materials and Methods: This is a retrospective study conducted on 90 patients with MetS at the University Medical Center Ho Chi Minh City from September 2023 to April 2024. MASLD was diagnosed based on the 2023 Delphi consensus criteria and MetS was diagnosed based on the criteria of International Diabetes Federation 2006. Results: The study population had an average age of 49.35 ± 8.39 years, with 67.78% female, and an average BMI of 26.23 ± 2.79 kg/m². There were 68 MetS patients meeting the MASLD criteria, accounting for 68.9%. The MetS patients with MASLD had significantly higher BMI compared to those without MASLD (p < 0.05). Conclusion: The study highlights the high prevalence of MASLD among MetS patients, especially in obese individuals, emphasizing the necessity of early screening and intervention to reduce the risk of progression to chronic liver diseases.
Article Details
Keywords
fatty liver, MASLD, metabolic syndrome
References
2. van Son KC, te Nijenhuis-Noort LC, Boone SC, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. Medicine (Baltimore). 2024;103(1): e34934. doi:10.1097/MD. 0000000000034934
3. Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population. J Clin Gastroenterol. 2017;51(2):160-166. doi:10. 1097/MCG.0000000000000666
4. Yang T, Yin J, Li J, Wang Q. The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention. Journal of Hepatology. 2024;80(2): e82-e85. doi:10.1016/ j.jhep.2023.09.030
5. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5): 469-480. doi:10.1111/j.1464-5491.2006.01858.x
6. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6): 1966-1986. doi:10.1097/HEP. 0000000000000520
7. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76-e77. doi:10.1016/j.jhep. 2023.08.026
8. Đỗ Minh Quân, Trần Thị Khánh Tường, Cao Đình Hưng, Đào Đức Tiến. Tỷ lệ bệnh gan nhiễm mỡ liên quan rối loạn chuyển hóa ở bệnh nhân đái tháo đường típ 2. VMJ. 2024;534(1B). doi:10.51298/vmj.v534i1B.8310
9. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1): 202-209. doi:10.1016/j.jhep.2020. 03.039
10. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10. 1002/hep.28431